dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Palazón Carrión, N. | es |
dc.creator | Henao-Carrasco, F. | es |
dc.creator | Nogales-Fernández, E. | es |
dc.creator | Álamo de la Gala, M. | es |
dc.creator | Vallejo Benítez, A. | es |
dc.creator | Chiesa, M. | es |
dc.date.accessioned | 2024-03-07T16:52:05Z | |
dc.date.available | 2024-03-07T16:52:05Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Cruz Merino, L.d.l., Palazón Carrión, N., Henao-Carrasco, F., Nogales-Fernández, E., Álamo de la Gala, M., Vallejo Benítez, A. y Chiesa, M. (2019). New horizons in breast cancer: the promise of immunotherapy. Clinical and Translational Oncology, 21 (2), 117-125. https://doi.org/10.1007/s12094-018-1907-3. | |
dc.identifier.issn | 1699-048X | es |
dc.identifier.issn | 1699-3055 | es |
dc.identifier.uri | https://hdl.handle.net/11441/155950 | |
dc.description.abstract | Immunology and immunotherapy of cancer is an expanding feld in oncology, with recent great achievements obtained
through the new successful approaches implemented to circumvent immune evasion, which is undoubtedly considered a novel
hallmark of cancer. Translational research in this topic has revealed targets that can be modulated in the clinical setting with
new compounds and strategies. Like most of the tumors, breast cancer is considered a complex and heterogeneous disease in
which host immune responses have been also recently demonstrated of critical relevance. T infltrating lymphocyte measure ment is suggested as a powerful new tool necessary to predict early breast cancer evolution, especially for the her2-positive
and triple-negative subtypes. Other biomarkers in tissue and peripheral blood are under intense scrutiny to ascertain their
eventual role as prognostic and/or predictive factors. This background has fueled the interest in developing clinical research
strategies to test activity of modern immunotherapy in breast cancer, which constitutes the main focus of this review. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.relation.ispartof | Clinical and Translational Oncology, 21 (2), 117-125. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Breast | es |
dc.subject | Cancer | es |
dc.subject | Immunology | es |
dc.subject | Immunotherapy | es |
dc.subject | Clinical | es |
dc.subject | Trials | es |
dc.title | New horizons in breast cancer: the promise of immunotherapy | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s12094-018-1907-3 | es |
dc.identifier.doi | 10.1007/s12094-018-1907-3 | es |
dc.contributor.group | Universidad de Sevilla. CTS151: Bioquímica médica. | es |
dc.journaltitle | Clinical and Translational Oncology | es |
dc.publication.volumen | 21 | es |
dc.publication.issue | 2 | es |
dc.publication.initialPage | 117 | es |
dc.publication.endPage | 125 | es |